Literature DB >> 19863249

Use of hepadnavirus core proteins as vaccine platforms.

David C Whitacre1, Byung O Lee, David R Milich.   

Abstract

The first virus-like particle to be tested for use as a vaccine carrier was based on the hepatitis B virus nucleocapsid protein. This viral subunit, while not infectious on its own, is a 36-nm particle that is highly immunogenic during a natural infection. The self-assembly and high degree of immunogenicity is maintained when expressed as a recombinant protein and, moreover, can confer a high degree of immunogenicity on foreign antigens linked to the particle, either chemically or genetically. This review describes the current state of the hepadnaviral core protein as a vaccine carrier.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19863249      PMCID: PMC2836209          DOI: 10.1586/erv.09.121

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  77 in total

1.  Insertion of foreign epitopes in HBcAg: how to make the chimeric particle assemble.

Authors:  L I Karpenko; V A Ivanisenko; I A Pika; N A Chikaev; A M Eroshkin; T A Veremeiko; A A Ilyichev
Journal:  Amino Acids       Date:  2000       Impact factor: 3.520

2.  The morphogenic linker peptide of HBV capsid protein forms a mobile array on the interior surface.

Authors:  Norman R Watts; James F Conway; Naiqian Cheng; Stephen J Stahl; David M Belnap; Alasdair C Steven; Paul T Wingfield
Journal:  EMBO J       Date:  2002-03-01       Impact factor: 11.598

3.  A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses.

Authors:  Andrea Jegerlehner; Alain Tissot; Franziska Lechner; Peter Sebbel; Iris Erdmann; Thomas Kündig; Thomas Bächi; Tazio Storni; Gary Jennings; Paul Pumpens; Wolfgang A Renner; Martin F Bachmann
Journal:  Vaccine       Date:  2002-08-19       Impact factor: 3.641

Review 4.  Hepatitis B virus biology.

Authors:  C Seeger; W S Mason
Journal:  Microbiol Mol Biol Rev       Date:  2000-03       Impact factor: 11.056

5.  Interaction of the hepatitis B core antigen and the innate immune system.

Authors:  Byung O Lee; Amy Tucker; Lars Frelin; Matti Sallberg; Joyce Jones; Cory Peters; Janice Hughes; David Whitacre; Bryan Darsow; Darrell L Peterson; David R Milich
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

6.  Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate.

Authors:  D R Milich; J Hughes; J Jones; M Sällberg; T R Phillips
Journal:  Vaccine       Date:  2001-12-12       Impact factor: 3.641

Review 7.  HBV core particles as a carrier for B cell/T cell epitopes.

Authors:  P Pumpens; E Grens
Journal:  Intervirology       Date:  2001       Impact factor: 1.763

8.  Preclinical evaluation of group B streptococcal polysaccharide conjugate vaccines prepared with a modified diphtheria toxin and a recombinant duck hepatitis B core antigen.

Authors:  L C Paoletti; D L Peterson; R Legmann; R J Collier
Journal:  Vaccine       Date:  2001-11-12       Impact factor: 3.641

9.  Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720.

Authors:  Michael Walther; Susanna Dunachie; Sheila Keating; Jenni M Vuola; Tamara Berthoud; Annette Schmidt; Carolin Maier; Laura Andrews; Rikke F Andersen; Sarah Gilbert; Ian Poulton; Daniel Webster; Filip Dubovsky; Eveline Tierney; Pramod Sarpotdar; Simon Correa; Angela Huntcooke; Geoffrey Butcher; Jack Williams; Robert E Sinden; George B Thornton; Adrian V S Hill
Journal:  Vaccine       Date:  2005-01-04       Impact factor: 3.641

10.  Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres.

Authors:  Yoshihiko Murata; Paula M Lightfoote; Robert C Rose; Edward E Walsh
Journal:  Virol J       Date:  2009-06-18       Impact factor: 4.099

View more
  39 in total

1.  Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7.

Authors:  Jerri do Carmo Caldeira; Alexander Medford; Rhonda C Kines; Christopher A Lino; John T Schiller; Bryce Chackerian; David S Peabody
Journal:  Vaccine       Date:  2010-04-29       Impact factor: 3.641

2.  SplitCore Technology Allows Efficient Production of Virus-Like Particles Presenting a Receptor-Contacting Epitope of Human IgE.

Authors:  A Zh Baltabekova; Zh S Shagyrova; A S Kamzina; M Voykov; Ye Zhiyenbay; E M Ramanculov; A V Shustov
Journal:  Mol Biotechnol       Date:  2015-08       Impact factor: 2.695

3.  Heterologous prime-boost immunization with vesiculovirus-based vectors expressing HBV Core antigen induces CD8+ T cell responses in naïve and persistently infected mice and protects from challenge.

Authors:  Carolina Chiale; Safiehkhatoon Moshkani; John K Rose; Michael D Robek
Journal:  Antiviral Res       Date:  2019-05-30       Impact factor: 5.970

4.  Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge.

Authors:  Jeanne H Schickli; David C Whitacre; Roderick S Tang; Jasmine Kaur; Heather Lawlor; Cory J Peters; Joyce E Jones; Darrell L Peterson; Michael P McCarthy; Gary Van Nest; David R Milich
Journal:  J Clin Invest       Date:  2015-03-09       Impact factor: 14.808

5.  Cryo-EM study of Hepatitis B virus core antigen capsids decorated with antibodies from a human patient.

Authors:  Eaazhisai Kandiah; Norman R Watts; Naiqian Cheng; Giovanni Cardone; Stephen J Stahl; Theo Heller; T Jake Liang; Paul T Wingfield; Alasdair C Steven
Journal:  J Struct Biol       Date:  2011-10-25       Impact factor: 2.867

Review 6.  Targeted immunomodulation using antigen-conjugated nanoparticles.

Authors:  Derrick P McCarthy; Zoe N Hunter; Bryce Chackerian; Lonnie D Shea; Stephen D Miller
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2014-03-10

Review 7.  Chronic hepatitis B: A wave of new therapies on the horizon.

Authors:  Timothy M Block; Siddhartha Rawat; Carol L Brosgart
Journal:  Antiviral Res       Date:  2015-06-22       Impact factor: 5.970

8.  Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen.

Authors:  Andrew G Diamos; Dalia Larios; Lauren Brown; Jacquelyn Kilbourne; Hyun Soon Kim; Divyasha Saxena; Kenneth E Palmer; Hugh S Mason
Journal:  Vaccine       Date:  2018-11-17       Impact factor: 3.641

Review 9.  Engineering virus-like particles as vaccine platforms.

Authors:  Kathryn M Frietze; David S Peabody; Bryce Chackerian
Journal:  Curr Opin Virol       Date:  2016-03-29       Impact factor: 7.090

Review 10.  Phage display creates innovative applications to combat hepatitis B virus.

Authors:  Wen Siang Tan; Kok Lian Ho
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.